Comparison of oral acrivastine versus loratadine for the treatment of chronic urticaria

Xin Wang,Linfeng Li
DOI: https://doi.org/10.3760/cma.j.issn.1673-4173.2015.06.003
2015-01-01
International Journal of Dermatology and Venereology
Abstract:Objective To compare the efficacy of oral acrivastine versus loratadine for the treatment of chronic urticaria.Methods Totally,110 patients with chronic urticaria were randomly divided into 2 groups:acrivastine group (n =56) treated with oral acrivastine capsules 8 mg thrice a day for 28 days,loratadine group (n =54) treated with oral loratadine tablets 10 mg once every day for 28 days.Therapeutic effects were evaluated on day 7,14 and 28 after the start of treatment.Results No significant differences were observed in the total response rate between the acrivastine group and loratadine group (73.5% (25/34) vs.67.6% (25/37),P > 0.05),but the proportion of unresponsive patients was significantly lower in the acrivastine group than in the loratadine group (5.9% (2/34) vs.32.4% (12/37),P < 0.05) on day 7.On day 7 and 14,the acrivastine group showed a significant increase in symptom score reducing indices (SSRIs) for wheal size and duration of episodes compared with the loratadine group (both P < 0.05).Both the patients and doctors were satisfied with the efficacy of acrivastine.There was no significant difference in the incidence of adverse reactions between the acrivastine group and loratadine group (5.4% (3/56) vs.5.6% (3/54),P > 0.05).Conclusion Acrivastine is safe and effective for the treatment of chronic urticaria.
What problem does this paper attempt to address?